Mankind Pharma Q3FY26 Revenue Jumps 11.5% to ₹10,835 Crore; Adj. EBITDA Margins at 25.9%
Mankind Pharma reported Q3FY26 revenue of ₹3,567 crore (up 11.5% YoY) and 9MFY26 revenue of ₹10,835 crore (up 18.7% YoY). Adjusted EBITDA margins stood at 25.9%. Domestic business grew 11.1% YoY, with strong performance in chronic therapies. Consumer Healthcare revenue increased 5.2% YoY.
Financial results, especially revenue growth and margin improvement, are material information for investors and can significantly impact the company's stock price and market perception.
The company reported strong year-on-year revenue growth and improved adjusted EBITDA margins, indicating positive financial performance. The commentary highlights confidence in future sustainable growth.
Mankind Pharma Limited announced its financial results for the third quarter and nine months of FY26, reporting a consolidated revenue of ₹10,835 crore for the nine-month period, an increase of 18.7% year-on-year. For Q3FY26, revenue from operations stood at ₹3,567 crore, up 11.5% YoY.
The company's domestic business grew by 11.1% YoY to ₹3,046 crore in Q3FY26, driven by growth in the base business and BSV consolidation. Chronic therapies showed strong performance with 16.7% growth in Cardiac and 14.4% in Anti-Diabetics. Consumer Healthcare revenue grew by 5.2% YoY to ₹203 crore in Q3FY26, regaining sequential growth momentum.
Adjusted EBITDA margins for Q3FY26 were reported at 25.9%, primarily due to improvements in domestic pharma and BSV consolidation. The company highlighted its confidence in delivering long-term sustainable growth anchored by four key pillars: steady base business, fast-growing specialty chronic, high potential OTC business, and the super specialty BSV portfolio.
The investor presentation also detailed key financial metrics, business updates, and strategic initiatives, including expansion in specialty and super specialty segments, and a focus on R&D. The company maintained its #1 rank in prescriptions over the last eight years with a prescription share of 15.2%.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.